A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

详细信息    查看全文

• 作者：Nadia Harbeck ; Steffen Saupe ; Elke Jäger…
• 关键词：Pegylated liposomal doxorubicin ; Capecitabine ; Metastatic breast cancer ; PELICAN
• 刊名：Breast Cancer Research and Treatment
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：161
• 期：1
• 页码：63-72
• 全文大小：695KB
• 刊物类别：Medicine
• 刊物主题：Oncology;
• 出版者：Springer US
• ISSN：1573-7217
• 卷排序：161

文摘

PurposeThe PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC).